Pharmacokinetic and Pharmacodynamic Considerations of Novel Antibiotic Agents for Pediatric Infections: A Narrative Review
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetic and Pharmacodynamic Considerations of Novel Antibiotic Agents for Pediatric Infections: A Narrative Review
Authors
Keywords
-
Journal
Surgical Infections
Volume 24, Issue 8, Pages 703-715
Publisher
Mary Ann Liebert Inc
Online
2023-10-14
DOI
10.1089/sur.2023.055
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram‐Negative Bacterial Infections: A Phase 1b, Open‐Label, Single‐Dose Clinical Trial
- (2023) John S. Bradley et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics and Pharmacodynamics of Tedizolid
- (2022) Khalid Iqbal et al. CLINICAL PHARMACOKINETICS
- Incidence, Clinicomicrobiological Characteristics, Risk Factors, and Treatment Outcomes of Bacterial Infections Following Liver Transplantation in Pediatrics: A Retrospective Cohort Study
- (2022) Afsaneh Vazin et al. Archives of Pediatric Infectious Diseases
- Activity of Tedizolid and Comparator Agents Against Gram-positive Isolates Causing Skin and Skin Structure Infections in Pediatric Patients in United States Hospitals (2015–2019)
- (2022) Cecilia Godoy Carvalhaes et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Optimizing Ceftaroline Dosing in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
- (2021) Shamir Kalaria et al. PHARMACOTHERAPY
- Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5‐Minute Infusion
- (2021) Todd A. Riccobene et al. Clinical Pharmacology in Drug Development
- Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination
- (2021) Hanine Mansour et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections
- (2021) Young-A. Heo DRUGS
- Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to
- (2021) Antonio C. Arrieta et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Ceftobiprole Perspective: Current and Potential Future Indications
- (2021) Tommaso Lupia et al. Antibiotics-Basel
- New Perspectives on Antimicrobial Agents: Ceftolozane/tazobactam
- (2021) Bryan D. Lizza et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients
- (2021) M. Trang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Optimizing Ceftobiprole Dosage in Pediatric Patients: A Model-Based Approach
- (2021) Christopher M. Rubino et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emerging resistance mechanisms for 4 types of common anti-MRSA antibiotics in Staphylococcus aureus: A comprehensive review
- (2021) Wan-Ting Liu et al. MICROBIAL PATHOGENESIS
- Competing off-loading mechanisms of meropenem from an l,d-transpeptidase reduce antibiotic effectiveness
- (2021) Trevor A. Zandi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
- (2021) Susanna Esposito et al. PEDIATRIC DRUGS
- Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime‐Avibactam in Pediatric Patients Aged 3 Months and Older
- (2021) Richard C. Franzese et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Sepsis Code: dodging mortality in a tertiary hospital
- (2021) Rosa Méndez et al. Revista Espanola de Quimioterapia
- Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections: Lessons Learned from the Development of Ceftazidime-Avibactam
- (2020) Jianguo Li et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Comparison of Treatment Outcomes Between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem/Cilastatin/Relebactam Versus Colistin Plus Imipenem/Cilastatin in Patients With Imipenem-Nonsusceptible Bacterial Infections
- (2020) Keith S. Kaye et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- An Update on Existing and Emerging Data for Meropenem-Vaborbactam
- (2020) Bethany R. Shoulders et al. CLINICAL THERAPEUTICS
- Ceftolozane/Tazobactam Treatment of Multidrug-resistant Pseudomonas aeruginosa Infections in Children
- (2020) Leah Molloy et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data
- (2020) Silvia Garazzino et al. Frontiers in Pediatrics
- No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials
- (2020) Kamal Hamed et al. Infection and Drug Resistance
- An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
- (2020) Eric Wenzler et al. Infectious Diseases and Therapy
- Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections
- (2020) Tanaya Bhowmick et al. Infectious Diseases and Therapy
- Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury
- (2020) Laura Butragueño-Laiseca et al. Antibiotics-Basel
- Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms
- (2019) Pranita D Tamma et al. Journal of the Pediatric Infectious Diseases Society
- Broad spectrum antibiotics in newborns increase multi-drug resistant infections.
- (2019) Almudena Alonso-Ojembarrena et al. JOURNAL OF CHEMOTHERAPY
- Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections
- (2019) Kajal B. Larson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and Efficacy of Ceftazidime–Avibactam in the Treatment of Children ≥3 Months to
- (2019) John S. Bradley et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Ceftobiprole for the treatment of infective endocarditis: a case series
- (2019) Carlo Tascini et al. Journal of Global Antimicrobial Resistance
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program
- (2019) Dee Shortridge et al. Journal of Global Antimicrobial Resistance
- Prevalence, Risk Factors And Treatment Of The Most Common Gram-Negative Bacterial Infections In Liver Transplant Recipients: A Review
- (2019) Mojtaba Shafiekhani et al. Infection and Drug Resistance
- in vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam Against Resistant Gram-Negative Bacilli
- (2018) Suzannah M. Schmidt-Malan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015)
- (2018) M.A. Pfaller et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections
- (2018) Matt Shirley DRUGS
- Ceftolozane/tazobactam: place in therapy
- (2018) Daniele Roberto Giacobbe et al. Expert Review of Anti-Infective Therapy
- Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives
- (2018) Femke de Velde et al. PHARMACOLOGICAL RESEARCH
- Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
- (2018) Sohita Dhillon DRUGS
- Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient
- (2018) Pier Giorgio Cojutti et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children with Proven or Suspected Gram-Negative Infection
- (2018) John S. Bradley et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Antibiotic discovery: History, methods and perspectives
- (2018) Guillaume André Durand et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA
- (2017) Karolyn S. Horn et al. Expert Opinion on Drug Metabolism & Toxicology
- Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review
- (2017) Felipe Francisco Tuon et al. INFECTION
- Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
- (2017) Matthew Sims et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections
- (2017) E. Hodille et al. MEDECINE ET MALADIES INFECTIEUSES
- Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis
- (2017) Jennifer Le et al. PEDIATRIC PULMONOLOGY
- A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics
- (2017) Paramita Sarkar et al. MedChemComm
- 401A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor RPX7009 Alone, Meropenem Alone, and both in Combination (Carbavance) TID for 7 days in Healthy Adult Subjects
- (2017) David Griffith et al. Open Forum Infectious Diseases
- Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation
- (2016) Marguerite L. Monogue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
- (2016) David van Duin et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations
- (2016) Antonio Torres et al. CLINICAL PHARMACOKINETICS
- Drug-Induced Hemolytic Anemia From Ceftazidime/Avibactam, A New Old Antimicrobial: A Case Report.
- (2016) Kimberly D. Leuthner et al. Open Forum Infectious Diseases
- Ceftolozane-tazobactam: A new-generation cephalosporin
- (2015) D. Cluck et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and Europe
- (2015) Daniel F. Sahm et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones
- (2015) Antonios Douros et al. Expert Opinion on Drug Metabolism & Toxicology
- Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents
- (2015) Eduardo Asín-Prieto et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- The β-Lactams Strike Back: Ceftazidime-Avibactam
- (2015) Evan J. Zasowski et al. PHARMACOTHERAPY
- Tedizolid: A new oxazolidinone antimicrobial
- (2014) J. J. Kisgen et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam
- (2014) Myra Wooley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections
- (2014) Gurudatt Chandorkar et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
- (2013) George G. Zhanel et al. DRUGS
- Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
- (2013) George G. Zhanel et al. DRUGS
- The Antibiotic Resistance and Prescribing in European Children Project
- (2013) Ann Versporten et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses
- (2012) Benjamin Miller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Differential Selection of Single-Step AmpC or Efflux Mutants of Pseudomonas aeruginosa by Using Cefepime, Ceftazidime, or Ceftobiprole
- (2010) A. M. Queenan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of MexXY Overexpression on Ceftobiprole Susceptibility in Pseudomonas aeruginosa
- (2009) E. Z. Baum et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Pharmacodynamics of Ceftobiprole, an Anti-MRSA Cephalosporin with Broad-Spectrum Activity
- (2009) Bindu Murthy et al. CLINICAL PHARMACOKINETICS
- Ceftobiprole: a new broad spectrum cephalosporin
- (2009) Ali A El Solh EXPERT OPINION ON PHARMACOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started